NCCN task force report: mTOR inhibition in solid tumors

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue SUPPL. 5, 2008, Pages

  Figlin, Robert A ^a   Brown, Elizabeth ^a   Armstrong, Andrew J ^a   Akerley, Wallace ^a   Benson III, Al B ^a   Burstein, Harold J ^a   Ettinger, David S ^a   Febbo, Phillip G ^a   Fury, Matthew G ^a   Hudes, Gary R ^a   Kies, Merrill S ^a   Kwak, Eunice L ^a   Morgan Jr , Robert J ^a   Mortimer, Joanne ^a   Reckamp, Karen ^a   Venook, Alan P ^a   Worden, Frank ^a   Yen, Yun ^a  

^a NONE

Author keywords

Cancer; Deforolimus; Everolimus; Malignancy; mTOR; mTOR inhibition; NCCN Clinical Practice Guidelines; Rapamycin; Targeted therapy; Temsirolimus

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AP 23573; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; INTERFERON; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VORINOSTAT; MTOR PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RIDAFOROLIMUS; TARGET OF RAPAMYCIN KINASE;

ACNE; ANEMIA; ANGIOGENESIS; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; ENDOMETRIUM CANCER; FATIGUE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METABOLIC DISORDER; MONOTHERAPY; MOUTH PAIN; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PERIPHERAL EDEMA; PNEUMONIA; PROSTATE CANCER; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY; PRACTICE GUIDELINE;

CLINICAL TRIALS AS TOPIC; EVEROLIMUS; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 54749149761     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484.
2. Bjornsti MA, Houghton PJ. The TOR pathway: a target for caner therapy. Nat Rev 2004;4:335-348.
3. Shaw RJ, Cantley LC. Ras, PI3K and mTOR signaling controls tumour cell growth. Nature 2006;441:424-430.
4. O'Reilly KE, Rojo R, She QB, et al. mTOR inhibition induced upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508.
5. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged sirolimus treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22:159-168.
6. Guertin DA, Sabatina DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
7. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005;102:8204-8209.
8. Kaelin WG. The von Hippel-lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007;13(2 Suppl):680s-684s.
9. George DJ, Kaelin WG. The von Hippel-Lindau protein, vascular endothelial growth factors, and kidney cancer. N Engl J Med 2003;349:419-421.
10. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006;10:159-170.
11. Abraham RT, Gibbons JJ. The mammalian target of sirolimus signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109-3114.
12. Ratain MJ, Napoli KL, Knightley Moshier K, et al. A phase 1b study of oral rapamycin (sirolimus) in patients with advanced malignancies [abstract]. J Clin Oncol 2007:25 (Suppl 1)
13. Jimeno A, Kulesza P, Cusatis G, et al. Pharmacodynamic-guided, modified continuous reassessment method (mCRM)-based, dose finding study of rapamycin in adult patients with solid tumors [abstract]. J Clin Oncol 2006: 24;(Suppl 1)
14. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-127.
15. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev 2006;5:671-688.
16. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of sirolimus kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-918.
17. Motzer RJ, Mazumdar M, Bacik I, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540.
18. Smith JW, Ko Y, Dutcher J, et al. Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma [abstract]. J Clin Oncol 2004;22(Suppl 1)
19. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 2007;356: 2271-2281.
20. Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon alpha [abstract]. J Clin Oncol 2007;25(Suppl 1)
21. Amato R, Misellati A, Khan M, Chiang S. Aphase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) [abstract]. J Clin Oncol 2006;24(Suppl 1)
22. Motzer RJ, Escudier B, Oudard S, et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma after progression on VEGFr-TKI therapy: results from a randomized, double blind, multicenter phase-III study [abstract]. J Clin Oncol 2008;26(Suppl 1)
23. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-5322.
24. Baselga J, Fumoleau P, Gil M, et al. Phase II, 3 arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Preliminary results [abstract]. J Clin Oncol 2004;22(Suppl 1)
25. Chow LW, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic disease [abstract]. Presented at the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas.
26. Baselga J, Semiglazov V van Dam P, et al. Phase II double blind randomized trial of daily oral RAD001 plus letrozole or placebo plus letrozole as neoadjuvant therapy for estrogen positive breast cancer [abstract]. Presented at the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Texas.
27. Gardner H, Bandaru R, Barrett C, et al. Biomarker analysis of pa phase II double blind randomized trial of daily oral RAD - 1 plus letrozole or placebo plus letrozole as neoadjuvant therapy for patients with estrogen receptor positive breast cancer. Presented at the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Texas.
28. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
29. Vermorken J, Moesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic squamous cell cancer of the head and neck when added to first line platinum based therapy [abstract]. J Clin Oncol 2007;25(Suppl 1)
30. Soulieres D, Senzer NN, Vokes E, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
31. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-1987.
32. Jimeno A, Kulesza P, Wheelhouse J, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007;96:952-959.
33. Nathan CO, Amirghahari N, Rong X, et al. Mammalian target of sirolimus inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 2007;67:2160-2168.
34. Yeager N, Brewer C, Cai KQ, et al. Mammalian target of sirolimus is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res 2008;68:444-449.
35. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-1154.
36. Yao JC, Phan A, Chang DZ, et al. Phase II study of RAD001 (everolimus) and depot octreotide in advanced low grade neuroendocrine carcinoma [abstract]. J Clin Oncol 2007;25(Suppl 1)
37. Llovet J, Ricci S, Mazzaferro P, et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial) [abstract]. J Clin Oncol 2007;25(Suppl 1)
38. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-4791.
39. Oza AM, Elit L, Biagi J, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCIC IND 160 [abstract]. J Clin Oncol 2006;24(Suppl 1)
40. Columbo N, McMeekin S, Schwartz P, et al. AP23573 as a single agent in advanced endometrial cancer [abstract]. J Clin Oncol 2007;25(Suppl 1)
41. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model [abstract]. Clin Cancer Res 2007;13:4261-4270.
42. Mabuchi S, Altomare DA, Connolly DC, et al. RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007;67:2408-2413.
43. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:5165-5171.
44. Cannistra SA, Matulonis US, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-5186.
45. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
46. David O, Jett J, LeBeau H, et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004;10:6865-6871.
47. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-3997.
48. Engelman JA, Jänne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005;102:3788-3793.
49. Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of sirolimus synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004;10:7031-7042.
50. Liu JL, Mao Z, LaFortune TA, et al. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res 2007;67:11054-11063.
51. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
52. Conde E, Angulo B, Tang M, et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 2006;12(3 Pt 1):710-717.
53. Buck E, Eyzaguirre A, Brown E, et al. Sirolimus synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006;5:2676-2684.
54. Phillips RJ, Mestas J, Gharaee-Kermani M, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/ PTEN/AKT/mammalian target of sirolimus signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 2005;280:22473-22481.
55. Papadimitrakopoulou V, Sorda JC, Douillard JY, et al. A phase II study of RAD001 monotherapy in patients with advanced non-small cell lung cancer failing prior platinum-based chemotherapy or prior chemotherapy and EGFR inhibitors [abstract]. J Clin Oncol 2007;25(Suppl 1)
56. Kris MG, Riely GJ, Azzoli CG, et al. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non small cell lung cancer who have smoked cigarettes: a phase II trial [abstract]. J Clin Oncol 2007;25(Suppl 1)
57. Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomized, phase II trial of two dose levels of temsirolimus in patients with extensive-stage small cell lung cancer who have responding or stable disease after induction chemotherapy. A trial of the Eastern Cooperative Oncology Group (E1 500). J Thorac Oncol 2007;2:1036-1041.
58. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
59. McMenamin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-4296.
60. Cairns F, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/ MMAC1 in primary prostate cancer. Cancer Res 1997; 57:4997-5000.
61. Li Y, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine kinase phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947.
62. Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998;4:811-815.
63. Trotman LC, Niki M, Dotan ZA, et al. PTEN dose dictates cancer progression in the prostate. PloS Biol 2003;1:E59.
64. Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007;128:157-170.
65. Ayala G, Thompson T, Yang G, et al. High Levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10:6572-6578.
66. Bedolla R, Prihoda TJ, Kreisberg JI, et al. Determining the risk of biochemical recurrent in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007;13:3860-3867.
67. Wang SI, Gao J, Lei Q, et al. Prostate specific deletion of the murine PTEN tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-221.
68. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of sirolimus inhibitor CC1-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 2825-2831.
69. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601.
70. Thomas GV, Horvath S, Smith BL, et al. Antibody based profiling of the phopshoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 2004;10:8351-8356.
71. Thomas GV, Speicher L, Reiter R, et al. Demonstration that temsirolimus preferentially inhibits the mTOR pathway in tumors of prostate cancer patients with PTEN deficiencies [abstract]. Presented at the 2005 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications; November 14-18, 2005; Philadelphia, Pennsylvania.
72. George DJ, Armstrong AJ, Creel P, et al. A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer [abstract]. Presented at the 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, California.